Quick Answer
Alaunos Therapeutics, Inc. reported Operating Income of -$4.22 million for fiscal year 2025.
Alaunos Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$4.22M | +12.2% |
| 2024 | -$4.81M | +86.0% |
| 2023 | -$34.27M | +2.4% |
| 2022 | -$35.10M | +54.7% |
| 2021 | -$77.55M | +3.5% |
| 2020 | -$80.36M | -38.9% |
| 2019 | -$57.86M | -7.3% |
| 2018 | -$53.91M | -0.8% |
| 2017 | -$53.49M | +67.6% |
| 2016 | -$165.31M | -37.6% |
| 2015 | -$120.10M | -176.1% |
| 2014 | -$43.50M | +24.6% |
| 2013 | -$57.71M | +43.5% |
| 2012 | -$102.17M | -43.1% |
| 2011 | -$71.40M | -190.9% |
| 2010 | -$24.55M | -102.5% |
| 2009 | -$12.12M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.19M | -3.2% | -14.2% |
| June 30, 2025 | -$1.04M | +10.9% | +4.9% |
| March 31, 2025 | -$1.09M | +37.3% | +5.0% |
| September 30, 2024 | -$1.15M | +86.7% | +1.4% |
| June 30, 2024 | -$1.17M | +85.4% | +33.1% |
| March 31, 2024 | -$1.74M | +82.0% | +79.9% |
| September 30, 2023 | -$8.66M | -4.8% | -8.5% |
| June 30, 2023 | -$7.98M | +13.5% | +17.5% |
- Alaunos Therapeutics, Inc. showed an increase of +12.2% in Operating Income compared to the prior fiscal year.
- Over the 2009–2025 period, Alaunos Therapeutics, Inc.’s operating income has grown by 65.1% (from -$12.12 million to -$4.22 million).
- The most recent figure is from Alaunos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: